---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-25-012575"
form_type: "8-K"
ticker: "ZOMDF"
cik: "0001684144"
company_name: "Zomedica Corp."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:39:21.281552+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zomedica Q3 2025 revenue $8.1M (+16% YoY); net loss narrows to $6.1M

## Summary
- Revenue $8.1M, up 16% YoY; gross margin 67%; Diagnostics segment grew 51%.
- Net loss $6.1M (down 9% YoY); adjusted EBITDA loss $3.9M.
- Cash and securities $54.4M; operating expenses reduced $0.5M in Q3.
- New Development Services segment generated $0.7M revenue in first quarter.
- Record revenue for 19th straight quarter; new distribution agreements in UK, Netherlands, Canada.

## SEC filing metadata
- accession: 0001654954-25-012575
- form_type: 8-K
- ticker: ZOMDF
- cik: 0001684144
- company_name: Zomedica Corp.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1684144/000165495425012575/0001654954-25-012575-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1684144/000165495425012575/zom_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-25-012575
- JSON: https://secwatch.observer/filing/0001654954-25-012575.json
- Plain text: https://secwatch.observer/filing/0001654954-25-012575.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.